Electra Therapeutics (NASDAQ:ETRA) Director Orbimed Advisors Llc Purchases 156,091 Shares of Company Stock

Key Points

  • Orbimed Advisors bought 156,091 Electra Therapeutics shares at an average $7.31 each, investing about $1.14 million. The purchase increased its stake by 3.08% to 5,220,762 shares.
  • Orbimed also bought shares on November 3 and 4; together, the three recent purchases totaled 472,571 shares. ETRA traded at $7.35 on Thursday, down $0.62 for the day.
  • Analysts surveyed by MarketBeat give the stock an average Buy rating and a $33.50 average price target, compared with its $7.35 trading price.
  • MarketBeat previews the top five stocks to own by December 1st.

Electra Therapeutics, Inc. (NASDAQ:ETRA - Get Free Report) Director Orbimed Advisors Llc purchased 156,091 shares of the stock in a transaction that occurred on Thursday, November 5th. The stock was bought at an average cost of $7.31 per share, with a total value of $1,141,025.21. Following the acquisition, the director owned 5,220,762 shares of the company's stock, valued at $38,163,770.22. This represents a 3.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The stock was bought at an average price of $7.53 per share, with a total value of $537,393.51.
  • On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $7.86 per share, for a total transaction of $1,926,588.18.
  • On Monday, September 21st, Orbimed Advisors Llc acquired 1,333,333 shares of Electra Therapeutics stock. The stock was purchased at an average price of $15.00 per share, for a total transaction of $19,999,995.00.

Electra Therapeutics Price Performance

Shares of NASDAQ ETRA traded down $0.62 during midday trading on Thursday, hitting $7.35. The stock had a trading volume of 524,786 shares, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a fifty-two week low of $6.86 and a fifty-two week high of $15.50.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ETRA. TD Cowen initiated coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a "buy" rating for the company. Jefferies Financial Group initiated coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They issued a "buy" rating and a $32.00 target price on the stock. HC Wainwright started coverage on shares of Electra Therapeutics in a research report on Monday, October 26th. They set a "buy" rating and a $30.00 price target for the company. Wall Street Zen raised shares of Electra Therapeutics to a "hold" rating in a research note on Saturday, September 26th. Finally, Evercore started coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an "outperform" rating and a $36.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $33.50.

Get Our Latest Report on ETRA

About Electra Therapeutics

(Get Free Report)

Electra Therapeutics, Inc NASDAQ: ETRA is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company's approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra's lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

See Also

Insider Buying and Selling by Quarter for Electra Therapeutics (NASDAQ:ETRA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Electra Therapeutics Right Now?

Before you consider Electra Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electra Therapeutics wasn't on the list.

While Electra Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines